Interestingly, the capacity for proximal PI3K blockade to potentiate immune function in specific contexts may nicely synergize with the broader ability of PI3K blockade inhibit tumor cell proliferation to make PI3K inhibitors particularly well suited to cancer treatment, reviewed in So and Fruman (2012). This evidence concerns the gene PIK3CD and cancer.